Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Octreotide

Therapeutic Applications in Patients with Pituitary Tumours

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Among somatostatin analogues, octreotide is the most extensively studied. Its pharmacodynamic properties are similar to those of somatostatin, with a wide spectrum of inhibitory effects on anterior pituitary function, pancreas and gut endocrine secretions, and gastrointestinal functions. Compared with the somatostatin, octreotide is highly resistant to enzymatic degradation and has a prolonged plasma half-life of about 100 minutes in humans, allowing its use in the long term treatment of various pathological conditions. Differential effects of octreotide on endocrine secretions such as growth hormone (GH) and insulin in healthy volunteers, as well as variable efficacy in the treatment of endocrine tumours, may relate to the distribution of somatostatin receptor subtypes.

The volume of distribution of octreotide ranges from 18 to 30L. Calculated serum distribution half-life ranges from 72 to 98 minutes. In blood, octreotide is mainly distributed in the plasma, 65% being bound to lipoproteins. After subcutaneous injection, absorption appears rapid and complete and bioavailability is about 100%. Mean peak plasma concentrations are between 2 and 4 µg/L in patients receiving 50 to 100µg. Peak concentrations are reached within 20 to 30 minutes and are 20 to 40% of corresponding values after intravenous injection. Peak concentrations and values for areas under the plasma concentration-time curve linearly correlate with the dosage. The elimination half-life is about 90 to 110 minutes. Total clearance in healthy individuals is about 160 ml/min (9.6 L/h). Hepatic metabolism of octreotide is extensive (30 to 40%) and about 11 to 20% of the dose is excreted unchanged in the urine.

Among pituitary tumours, GH- and thyrotrophin-secreting adenomas are the most sensitive to octreotide. Octreotide has been widely used in the treatment of acromegaly. 50 to 80% of the patients respond to daily multiple subcutaneous injections with insulin-like growth factor-1 (IGF1) levels being normalised in about 40 to 50% of them. Neither desensitisation with long term therapy nor rebound phenomena after octreotide withdrawal have been noticed in these studies.

Even in patients with partial response, clinical symptoms improved. Octreotide daily dosages needed to achieve optimum responses may vary greatly from one patient to another. In a minority of patients complete resistance to octreotide was observed and was not always related to the absence of somatostatin receptors in the tumour. The wide spectrum of effects of octreotide in humans accounts for adverse effects seen during long term treatment, primarily cholelithiasis.

Other modes of administration are efficient. In particular, continuous subcutaneous infusion allows the use of a smaller dosage, but is more effective than multiple injections in some patients. Intranasal administration is now also being investigated and seems promising.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotrophin hypersecretion. Journal of Endocrinological Investigation 13: 257–261, 1990

    PubMed  CAS  Google Scholar 

  • Anderson JV, Catnach S, Lowe DG, Fairclough PD, Besser GM, et al. Prevalence of gastritis in patients with acromegaly: untreated and during treatment with octreotide. Clinical Endocrinology 37: 227–232, 1992

    Article  PubMed  CAS  Google Scholar 

  • Arosio M, Guglielmino L, Bazoni N, Ambrosi B. Effects of SMS 201–995 administration in 8 patients with acromegaly. Journal of Endocrinological Investigation 8 (Suppl. 3): 192, Abstract 203, 1985

    Google Scholar 

  • Arosio M, Bazzoni N, Ambrosi B, Faglia G. Acute hepatitis after treatment of acromegaly with octreotide. Lancet 2: 1498, 1988

    Article  PubMed  CAS  Google Scholar 

  • Barkan AL. Acromegaly: diagnosis and therapy. Endocrinology and Metabolism Clinics of North America 18: 277–310, 1989

    PubMed  CAS  Google Scholar 

  • Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ. Treatment of acromegaly with the long acting somatostatin analogue SMS 201–995. Journal of Clinical Endocrinology and Metabolism 66: 16–23, 1988a

    Article  PubMed  CAS  Google Scholar 

  • Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201–995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. Journal of Clinical Endocrinology and Metabolism 67: 1040–1048, 1988b

    Article  PubMed  CAS  Google Scholar 

  • Barnard LB, Grantham WG, Lamberton P, O’Dorisio TM, Jackson IM. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201–995). Annals of Internal Medicine 105: 856–861, 1986

    PubMed  CAS  Google Scholar 

  • Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, et al. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sciences 31: 1133–1140, 1982

    Article  PubMed  CAS  Google Scholar 

  • Beck-Peccoz P, Mariotti S, Guillausseau PJ, Medri G, Piscitelli G, et al. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analogue SMS 201–995. Journal of Clinical Endocrinology and Metabolism 68: 208–214, 1989

    Article  PubMed  CAS  Google Scholar 

  • Bell GI, Reisine T. Molecular biology of somatostatin receptors. Trends in Neurosciences 16: 34–38, 1993

    Article  PubMed  CAS  Google Scholar 

  • Bertagna X, Favrod-Coune C, Escourolle H, Beuzeboc P, Christoforov B, et al. Suppression of ectopic adrenocorticotropin secretion by the long-acting somatostatin analog octreotide. Journal of Clinical Endocrinology and Metabolism 68: 988–991, 1989

    Article  PubMed  CAS  Google Scholar 

  • Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, et al. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretion. Journal of Clinical Endocrinology and Metabolism 75: 540–546, 1992a

    Article  PubMed  CAS  Google Scholar 

  • Bertherat J, Chanson P, Dewailly D, Enjalbert A, Jaquet P, et al. Resistance to somatostatin (SRIH) analog therapy in acromegaly: reevaluation of the correlation between the SRIH receptor status of the pituitary tumor and the in vivo inhibition of GH secretion in response to SRIH analog. Hormone Research 38: 94–99, 1992b

    Article  PubMed  CAS  Google Scholar 

  • Brazeau P, Vale W, Burgus R, Ling N, Butcher M, et al. Hypothalamic peptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77–79, 1973

    Article  PubMed  CAS  Google Scholar 

  • Buscail LE, Puel-Bousquet C, Harris AG, Tauber JP, Escourrou JR, et al. Effets sur la lithogénèse biliaire du traitement au long cours par octreotide (SMS 201–995) chez des patients acromégales. Gastroentérologie Clinique et Biologique 15: 800–804, 1991

    PubMed  CAS  Google Scholar 

  • Chanson P, Chauveau ME, Duranteau L, Chedin P, Timsit J, et al. Tolérance digestive du traitement au long cours par octreotide chez 24 acromégales. Annales d’Endocrinologie 52: A65, 1991

    Google Scholar 

  • Chanson P, Timsit J, Benoit O, Augendre B, Moulonguet M, et al. Rapid improvement in sleep apnoea of acromegaly after short term treatment with somatostatin analogue SMS 201–995. Lancet 1: 1270–1271, 1986

    Article  PubMed  CAS  Google Scholar 

  • Chanson P, Timsit J, Masquet C, Warnet A, Guillausseau PJ, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Annals of Internal Medicine 113: 921–925, 1990

    PubMed  CAS  Google Scholar 

  • Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas: a follow-up of 52 patients. Annals of Internal Medicine 119: 236–240, 1993

    PubMed  CAS  Google Scholar 

  • Chiodini PG, Cozzi R, Dallabonzana D, Oppizi G, Verde G, et al. Medical treatment of acromegaly with SMS 201–995, a somatostatin analog: a comparison with bromocriptine. Journal of Clinical Endocrinology and Metabolism 64: 447–453, 1987

    Article  PubMed  CAS  Google Scholar 

  • Christensen SE, Weeke J, Orskov, Moller N, Flyvbjerg A, et al. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201–995 versus subcutaneous injection schedule in acromegalic patients. Clinical Endocrinology 27: 297–306, 1987

    Article  PubMed  CAS  Google Scholar 

  • Christensen SE, Weeke J, Orskov H. Long-term efficacy and tolerability of octreotide treatment in acromegaly. Metabolism 41 (Suppl. 2): 44–50, 1992

    Article  PubMed  CAS  Google Scholar 

  • Clark RV, York RM, Lauer RM, Welch Jr NS. Control of Cushing’s syndrome secondary to ectopic ACTH with octreotide. Clinical Research 38: 943A, 1990

    Google Scholar 

  • Cohen R, Chanson P, Bruckert E, Timsit J, Legrand A, et al. Effects of octreotide in lipid metabolism in acromegaly. Hormone and Metabolic Research 24: 397–401, 1992

    Article  PubMed  CAS  Google Scholar 

  • Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. New England Journal of Medicine 317: 12–17, 1987

    Article  PubMed  CAS  Google Scholar 

  • Davies RR, Miller M, Turner SJ, Goodship THJ, Cook DB, et al. Effects of somatostatin analogue SMS 201–995 in normal man. Clinical Endocrinology 24: 665–674, 1986

    Article  PubMed  CAS  Google Scholar 

  • Del Pozo E, Neufeld M, Schlüter K, Tortosa F, Clarenbach P, et al. Endocrine profile of a long-acting somatostatin derivative SMS 201–995: study in normal volunteers following subcutaneous administration. Acta Endocrinologica 111: 433–439, 1986

    PubMed  Google Scholar 

  • Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wass HAH. Gallstones during octreotide therapy. Metabolism 41 (Suppl. 2): 22–33, 1992

    Article  PubMed  CAS  Google Scholar 

  • Epelbaum J. Somatostatin receptors in the central nervous system. In Weil et al. (Eds) Somatostatin basic and clinical aspects of neuroscience, Vol. 4, pp. 17–28, Springer-Verlag, Berlin-Heidelberg, 1992

    Google Scholar 

  • Eastman RC, Gorden P, Roth J. Conventional supervoltage irradiation is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism 48: 931–939, 1979

    Article  PubMed  CAS  Google Scholar 

  • Eastman RC, Arakaki RF, Shawker T, Schock R, Roach P, et al. A prospective examination of octreotide-induced gallbladder changes in acromegaly. Clinical Endocrinology 36: 265–269, 1992

    Article  PubMed  CAS  Google Scholar 

  • Erlinger S, Chanson P, Dumont M, Ponsot P, Warnet A, et al. Effects of octreotide on biliary lipid composition and the occurrence of cholesterol crystals in patients with acromegaly: a prospective study. Digestive Diseases and Science, in press, 1993

    Google Scholar 

  • Feek CM, McLelland J, Seth J, Toft AD, Irvine WJ, et al. How effective is external pituitary irradiation for growth-hormone-secreting pituitary tumors? Clinical Endocrinology 20: 401–408, 1984

    Article  PubMed  CAS  Google Scholar 

  • Fredstorp L, Harris AG, Haas G, Werner S. Short-term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo controlled study on its effects. Journal of Clinical Endocrinology and Metabolism 71: 1189–1194, 1990

    Article  PubMed  CAS  Google Scholar 

  • Flicker G, Bruns C, Munzer J, Briner U, Albert R, et al. Intestinal absorption of the octapeptide SMS 201–995 visualized by florescence derivatization. Gastroenterology 100: 1544–1552, 1991

    Google Scholar 

  • Fricker G, Drewe J, Vonderscher J, Kissel T, Beglinger C. Enterai absorption of octreotide. British Journal of Pharmacology 105: 783–786, 1992

    Article  PubMed  CAS  Google Scholar 

  • Frohman LA. Therapeutic options in acromegaly. Journal of Clinical Endocrinology and Metabolism 72: 1175–1181, 1991

    Article  PubMed  CAS  Google Scholar 

  • Fuessl HS, Burrin JM, Williams G, Adrian TE, Bloom SR. The effects of a long-acting somatostatin analogue (SMS 201–995) on intermediary metabolism and gut hormones after a test meal in normal subjects. Alimentation Pharmacology and Therapeutics 1: 321–330, 1987a

    Article  CAS  Google Scholar 

  • Fuessl HS, Carolan G, Williams G, Bloom SR. Effect of a long-acting somatostatin analogue (SMS 201–995) on postprandial gastric emptying of 99m Tc-Tin colloid and mouth-to-caecum transit time in man. Digestion 36: 101–107, 1987b

    Article  PubMed  CAS  Google Scholar 

  • Fuessl H, Domin J, Bloom SR. Oral absorption of the somatostatin analogue SMS 201–995: theoretical and practical implications. Clinical Science 72: 255–257, 1987c

    PubMed  CAS  Google Scholar 

  • George SR, Hegele RA, Burrow GN. The somatostatin analogue SMS 201–995 in acromegaly: prolonged preferential suppression of growth hormone but not pancreatic hormones. Clinical and Investigative Medicine 10: 309–315, 1987

    PubMed  CAS  Google Scholar 

  • Gorden P, Comi RJ, Maton PN, Go VLW. Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and nonneoplastic diseases of the gut. Annals of Internal Medicine 110: 35–50, 1989

    PubMed  CAS  Google Scholar 

  • Guillausseau PJ, Chanson P, Timsit J, Warnet A, Lajeunie E, et al. Visual improvement with SMS 201–995 in a patient with a thyrotropin-secreting pituitary adenoma. New England Journal of Medicine 317: 53–54, 1987

    Article  PubMed  CAS  Google Scholar 

  • Gyr KE, Meier R. Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. Metabolism 41 (Suppl. 2): 17–21, 1992

    Article  PubMed  CAS  Google Scholar 

  • Ho KY, Weissberger J, Marbach P, Lazarus. Therapeutic efficacy of the somatostatin analog SMS 201–995 (octreotide) in acromegaly. Annals of Internal Medicine 112: 173–181, 1990

    PubMed  CAS  Google Scholar 

  • Ho KYK, Jenkins AB, Furier SM, Borkman M, Chiholm DJ, et al. Impact of octreotide, a long-acting somatostatin analogue on glucose tolerance and insulin sensitivity in acromegaly. Clinical Endocrinology 36: 271–279, 1992

    Article  PubMed  CAS  Google Scholar 

  • Hofland LJ, Van Koetsveld PM, Van Vroonhoven CCJ, Stefanko SZ, Lamberts SWJ, et al. Heterogeneity of growth hormone release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201–995, GHRH and TRH. Journal of Clinical Endocrinology and Metabolism 68: 613–619, 1989

    Article  PubMed  CAS  Google Scholar 

  • Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. Acta Endocrinologica 120: 187–194, 1989

    PubMed  CAS  Google Scholar 

  • Ikuyama S, Nawata H, Kato KI, Ibayashi H, Nakagaki H. Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. Journal of Clinical Endocrinology and Metabolism 62: 729–733, 1986

    Article  PubMed  CAS  Google Scholar 

  • Invitti C, De Martin M, Brunani A, Piolini M, Cavagnini F. Treatment of Cushing’s syndrome with the long-acting somatostatin analogue SMS 201–995. Clinical Endocrinology 32: 275–281, 1990

    Article  PubMed  CAS  Google Scholar 

  • James RA, Chatterjee S, White MC, Hall K, Moller N, et al. Continuous infusion of octreotide in acromegaly. Lancet 2: 1083–1087, 1989

    Article  PubMed  CAS  Google Scholar 

  • James RA, Moller N, Chatterjee, White M, Kendall-Taylor P, et al. Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide. Diabetic Medicine 8: 517–523, 1991

    Article  PubMed  CAS  Google Scholar 

  • Johnston DG, Davies RR, Turner SJ. Effects of somatostatin and SMS 201–995 on carbohydrate metabolism in normal man. Scandinavian Journal of Gastroenterology 21 (Suppl. 119): 158–165, 1986

    Article  Google Scholar 

  • Kallivretakis N, Yotis A, Del Pozo E, Marbach P, Mountokalakis T, et al. Pharmacokinetics of SMS 201–995 in normal subjects and in patients with severe renal failure. Neuroendocrinology Letters 7: 92, 1985

    Google Scholar 

  • Karnes WE, Maxwell V, Sytnik B, Chew P, Walsh JH. Prolonged inhibition of meal-stimulated acid secretion and gastrin release following single subcutaneous administration of octreotide (SMS 201–995) in man. Alimentary Pharmacology and Therapeutics 3: 527–538, 1989

    Article  PubMed  CAS  Google Scholar 

  • Kelijman M, Williams TC, Downs TR, Frohman LA. Comparison of the sensitivity of growth hormone secretion to somatostatin in vivo and in vitro in acromegaly. Journal of Clinical Endocrinology and Metabolism 67: 958–963, 1988

    Article  PubMed  CAS  Google Scholar 

  • Köhler E, Duberow-Drewe M, Drewe J, Ribes G, Loubatières-Mariani MM, et al. Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage. European Journal of Clinical Pharmacology 33: 167–171, 1987

    Article  PubMed  Google Scholar 

  • Kutz K, Nüesch E, Rosenthaler J. Pharmacokinetics of SMS 201–995 in healthy subjects. Scandinavian Journal of Gastroenterology 21 (Suppl. 119): 65–72, 1986

    Article  Google Scholar 

  • Lamberts SWJ, Oosterom R, Neufeld M, Del Pozo E. The somatostatin analogue SMS 201–995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion. Journal of Clinical Endocrinology and Metabolism 60: 1161–1165, 1985a

    Article  PubMed  CAS  Google Scholar 

  • Lamberts SWJ, Uitterlinden P, Verschoor L, Van Dongen NJ, Del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995. New England Journal of Medicine 313: 1576–1580, 1985b

    Article  PubMed  CAS  Google Scholar 

  • Lamberts SWJ, Del Pozo E. Acute and long-term effects of SMS 201–995 in acromegaly. Scandinavian Journal of Gastroenterology 21 (Suppl. 119): 141–148, 1986

    Article  Google Scholar 

  • Lamberts SWJ, Zweens M, Verschoor L, Del Pozo E. A comparison among growth hormone lowering effects in acromegaly of the somatostatin analog SMS 201–995, bromocriptine and the combination of both drugs. Journal of Clinical Endocrinology and Metabolism 63: 16–19, 1986

    Article  PubMed  CAS  Google Scholar 

  • Lamberts SWJ, Uitterlinden P, Verleun J. Relationship between growth hormone and somatomedin C levels in untreated acromegaly after surgery and radiotherapy and during medical therapy with Sandostatin (SMS 201–995). European Journal of Clinical Investigation 17: 354–359, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Lamberts SWJ, Uitterlinden P, Del Pozo E. SMS 201–995 induces a continuous decline in circulating growth hormone and somatomedin C levels during therapy of acromegaly for over two years. Journal of Clinical Endocrinology and Metabolism 65: 703–710, 1987b

    Article  PubMed  CAS  Google Scholar 

  • Lamberts SWJ. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of pituitary tumors. Endocrine Reviews 9: 417–436, 1988a

    Article  PubMed  CAS  Google Scholar 

  • Lamberts SWJ. Studies on the acute and chronic effects of Sandostatin in acromegaly. In Lamberts SWJ (Ed.) Sandostatin in the treatment of acromegaly, pp. 61–74, Springer-Verlag, Berlin-Heidelberg, 1988b

    Chapter  Google Scholar 

  • Lamberts SWJ, Uitterlinden P, Klijn JMG. The effect of the long-acting somatostatin analogue SMS 201–995 on ATH secretion in Nelson’s syndrome and Cushing’s syndrome. Acta Endocrinologica 120: 760–766, 1989

    PubMed  CAS  Google Scholar 

  • Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A, et al. Disposition of Sandostatin, a new synthetic somatostatin analogue in rats. Drug Metabolism and Disposition 17: 699–703, 1989

    PubMed  CAS  Google Scholar 

  • Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, et al. Effects of the somatostatin analogue Sandostatin (SMS 201–995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 36: 108–124, 1987

    Article  PubMed  CAS  Google Scholar 

  • Lightman SL, Fox P, Dunne MJ. The effects of SMS 201–995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers. Scandinavian Journal of Gastroenterology 21 (Suppl. 119): 84–95, 1986

    Article  Google Scholar 

  • Liuzzi A, Dallabonzana D, Oppizzi G, Arrigoni GL, Cozzi R, et al. Is there a real medical treatment for ‘non secreting pituitary adenomas’? In Faglia G, et al. (Eds) Pituitary adenomas: new trends in basic and clinical research, pp. 383–390, Elsevier Science Publishers BV, Amsterdam, 1991

    Google Scholar 

  • Londong W, Angerer M, Kutz K, Landgraf R, Londong V. Diminishing efficacy of octreotide (SMS 201–995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 96: 713–722, 1989

    PubMed  CAS  Google Scholar 

  • Longnecker SM. Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia. Drug Intelligence and Clinical Pharmacy 22: 99–106, 1988

    PubMed  CAS  Google Scholar 

  • Lorcy Y, Delambre C, Leguerrier AM, Bouyaux M, Deidier A, et al. Traitement de la maladie de Cushing par un analogue de la somatostatine (SMS 201–995). Quatre observations. Annales d’Endocrinologie 50: 311, Abstract 106, 1989

    Google Scholar 

  • McGregor AR, Throughton WD, Donald RA, Espiner EA. Effect of the somatostatin analogue SMS 201–995 on faecal fat excretion in acromegaly. Hormone and Metabolic Research 22: 55–56, 1990

    Article  PubMed  CAS  Google Scholar 

  • Marbach P, Bauer W, Briner U, Döpfner W, Petcher T, et al. Structure-function relationships of somatostatin analogs. Metabolism 29: 54–58, 1988

    CAS  Google Scholar 

  • Marbach P, Briner U, Lemaire M, Schweitzer A, Terasaki T. From somatostatin to Sandostatin: pharmacodynamics and pharmacokinetics. Metabolism 41 (Suppl. 2): 7–10, 1992

    Article  PubMed  CAS  Google Scholar 

  • Mazer NA. Pharmacokinetic and pharmacodynamic aspects of polypeptide delivery. Journal of Controlled Release 11: 343–356, 1990

    Article  CAS  Google Scholar 

  • Melmed S. Acromegaly. New England Journal of Medicine 322: 966–975, 1990

    Article  PubMed  CAS  Google Scholar 

  • Merceur C, Kerlan V, Esnault S, Mabin D, Bercovici JP. Acromégalie et syndrome d’apnées du sommeil: l’octreotide, indication d’urgence. Revue Française d’Endocrinologie Clinique 31: 277–281, 1990

    Google Scholar 

  • Nicholls J, Wynick D, Domin J, Sandler LM, Bloom SR. Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201–995) in acromegaly. Clinical Endocrinology 32: 545–550, 1990

    Article  PubMed  CAS  Google Scholar 

  • Orskov H, Christensen SE, Weeke J, Kaal A, Harris AG. Effects of antibodies against octreotide in two patients with acromegaly. Clinical Endocrinology 34: 395–398, 1991

    Article  PubMed  CAS  Google Scholar 

  • Patel SR, Kvols LK, Peterson DA, Gilbertson DT, Moertel CG. Comparison of the pharmacokinetics of octreotide injected at two subcutaneous sites. Journal of the National Cancer Institute 81: 1926–1929, 1989

    Article  PubMed  CAS  Google Scholar 

  • Pieters GF, Smals AE, Smals AG, Von Gennep JA, Kloppenborg PW. The effect of minisomatostatin on anomalous growth hormone responses in acromegaly. Acta Endocrinologica 114: 537–542, 1987

    PubMed  CAS  Google Scholar 

  • Plewe G, Beyer J, Krause U, Neufeld M, Del Pozo E. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201–995 in acromegaly. Lancet 2: 782–784, 1984

    Article  PubMed  CAS  Google Scholar 

  • Plöckinger U, Dienemann D, Quabbe HJ. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 71: 1658–1562, 1990

    Article  PubMed  Google Scholar 

  • Quabbe HJ, Plöckinger U. Dose-response study and long-term effects of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. Journal of Clinical Endocrinology and Metabolism 68: 873–881, 1989

    Article  PubMed  CAS  Google Scholar 

  • Reichlin S. Somatostatin. New England Journal of Medicine 309: 1495–1501, 1556-1563, 1983

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients. Journal of Clinical Endocrinology and Metabolism 59: 1148–1151, 1984

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlates with adenoma somatostatin receptor status. Journal of Clinical Endocrinology and Metabolism 68: 844–850, 1989

    Article  PubMed  CAS  Google Scholar 

  • Reznik Y, Allali-Zerah V, Chayvialle JE, Leroyer R, Leymarie P, et al. Food-dependent Cushing’s syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. New England Journal of Medicine 327: 981–986, 1992

    Article  PubMed  CAS  Google Scholar 

  • Roelfsema F, Frölien M, De Boer H, Harris AG. Octreotide treatment in acromegaly: a comparison between pen-treated and pump-treated patients in a cross-over study. Acta Endocrinologica 125: 43–48, 1991

    PubMed  CAS  Google Scholar 

  • Ross DA, Wilson CB. Results of transsphenoidal microsurgery for growth-hormone-secreting pituitary adenomas in a series of 214 patients. Journal of Neurosurgery 68: 854–867, 1988

    Article  PubMed  CAS  Google Scholar 

  • Sandier LM, Burrin JM, Williams G, Joplin GF, Carr DH, et al. Effective long-term treatment of acromegaly with a long-acting somatostatin analogue SMS 201–995. Clinical Endocrinology 26: 85–95, 1987

    Article  Google Scholar 

  • Sassolas G, Harris AG, James-Deidier A, the French SMS 201–995 Acromegaly Study Group. Long-term effect of incremental doses of the somatostatin analog SMS 201–995 in 58 acromegalic patients. Journal of Clinical Endocrinology and Metabolism 71: 391–397, 1990

    Article  PubMed  CAS  Google Scholar 

  • Shi YF, Harris AG, Zhu XF, Deng JY. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201–995 in ten acromegalic patients. Clinical Endocrinology 32: 695–705, 1990

    Article  PubMed  CAS  Google Scholar 

  • Sosset C, Fredenrich A, Sadoul JL, Freychet P. Acute pancreatitis after octreotide therapy: report of two cases. Proceedings of the Ninth International Congress of Endocrinology, Nice, August 30–September 5, 1992. Abstract no. P 08-01-165, p. 320, 1992

  • Tauber JP, Babin T, Tauber MT, Vigoni F, Bonafe A, et al. Long-term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 68: 917–924, 1989

    Article  PubMed  CAS  Google Scholar 

  • Thuesen, Christensen SE, Weeke J, Orskov H, Henningsen P. The cardiovascular effects of octreotide treatment in acromegaly. An echocardiographic study. Clinical Endocrinology 30: 619–628, 1989

    Article  PubMed  CAS  Google Scholar 

  • Timsit J, Chanson P, Larger E, Duet M, Mosse A, et al. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201–995) on the diurnal GH profile in acromegaly. Acta Endocrinologica 116: 108–112, 1987

    PubMed  CAS  Google Scholar 

  • Timsit J, Chanson P, Harris AG, Grass P, Guillausseau PJ, et al. Short-term continuous infusion of octreotide in acromegaly: pharmacokinetics and prediction of the response to long-term treatment. Hormome and Metabolic Research 23: 48–49, 1991

    Article  CAS  Google Scholar 

  • Tolis G, Yotis A, Del Pozo E. Therapeutic efficacy of somatostatin analogue (SMS 201–995) in active acromegaly. Journal of Neurosurgery 65: 37–40, 1986

    Article  PubMed  CAS  Google Scholar 

  • Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330: 566–568, 1987

    Article  PubMed  CAS  Google Scholar 

  • Vale W, Rivier J, Ling N, Brown M. Biologic and immunologic activities and applications of somatostatin analogues. Metabolism 27: 1391–1401, 1978

    Article  PubMed  CAS  Google Scholar 

  • Van Liessum PA, Hopman WPM, Pieters GFFM, Jansen JBMJ, Smals AGH, et al. Postprandial gallbladder motility during longterm treatment with the long-acting somatostatin analog SMS 201–995 in acromegaly. Journal of Clinical Endocrinology and Metabolism 69: 557–562, 1989a

    Article  PubMed  Google Scholar 

  • Van Liessum PA, Pieters GF, Smals AG, Hermus AR, Benraad TJ, et al. Single-dose response study of the somatostatin analogue octreotide in acromegaly. Acta Endocrinologica 121: 714–720, 1989b

    PubMed  Google Scholar 

  • Van Liessum PA, Hopman WPM, Pieters GFF, Smals AGH, Tangerman A, et al. Postprandial exocrine pancreatic function during long-term treatment with the somatostatin analogue SMS 201–995 in acromegalic patients. European Journal of Clinical Investigation 20: 348–353, 1990

    Article  PubMed  Google Scholar 

  • Vance ML, Asplin CM, Chitwood J, Frohman LA, O’Dorisio T, et al. SMS 201–995: studies in acromegaly and in normal men. Scandinavian Journal of Gastroenterology 21 (Suppl. 119): 243–248, 1986

    Article  Google Scholar 

  • Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide: results of the International Multicenter Acromegaly Study Group. Archives of Internal Medicine 151: 1573–1578, 1991

    Article  PubMed  CAS  Google Scholar 

  • Wagenaar A, Harris AG, Van der Lely A, Lamberts SWJ. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinologica 125: 637–642, 1991

    PubMed  CAS  Google Scholar 

  • Warnet A, Timsit J, Chanson P, Guillausseau PJ, Zanfirescu F, et al. The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas. Journal of Neurosurgery 71: 687–690, 1989

    Article  PubMed  CAS  Google Scholar 

  • Warnet A. The role of octreotide (Sandostatin) in non growth hormone-, non thyroid-stimulating hormone- and non prolactin-secreting adenomas. Metabolism 41 (Suppl. 2): 59–61, 1992

    Article  PubMed  CAS  Google Scholar 

  • Wass JAH, Lykas N, Besser GM. Somatostatin octapeptide SMS 201–995 in the medical treatment of acromegaly. Scandinavian Journal of Gastroenterology 21 (Suppl. 119): 136–140, 1986

    Article  Google Scholar 

  • Weeke J, Christensen SE, Orskov H, Kaal A, Pedersen MM, et al. A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 75: 163–169, 1992

    Article  PubMed  CAS  Google Scholar 

  • Wemeau JL, Dewailly D, Leroy R, D’Herbomez M, Mazzuca M, et al. Long-term treatment with the somatostatin analog SMS 201–995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma. Journal of Clinical Endocrinology and Metabolism 66: 638–641, 1988

    Article  Google Scholar 

  • Williams G, Ball JA, Burrin JM, Joplin GF, Bloom SR. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201–995. Lancet 2: 774–778, 1986

    Article  PubMed  CAS  Google Scholar 

  • Wynick D, Bloom SR. The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism 73: 1–3, 1991

    Article  PubMed  CAS  Google Scholar 

  • Yamada Y, Post SR, Wang K, Tager HS, Bell GI, et al. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. Proceedings of the National Academy of Sciences of the United States of America 89: 251–255, 1992

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Endocrinology, Hôpital Lariboisière, 2 rue Ambroise Paré, F.75475, Paris Cedex 10, France

    Philippe Chanson

  2. Department of Clinical Immunology and INSERM U 25, Hôpital Necker, Paris, France

    José Timsit

  3. Department of Medicine Cedars-Sinai Medical Center, Division of Clinical Pharmacology, Los Angeles, California, USA

    Alan G. Harris

Authors
  1. Philippe Chanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Timsit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alan G. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chanson, P., Timsit, J. & Harris, A.G. Clinical Pharmacokinetics of Octreotide. Clin. Pharmacokinet. 25, 375–391 (1993). https://doi.org/10.2165/00003088-199325050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199325050-00004

Keywords

Search

Navigation